The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

By L. Adams, J. Lymp, J. S. St. Sauver, S. Sanderson, K. Lindor, A. Feldstein, P. Angulo. Gastroenterology, 2005

2,924 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/55eefc784a108c6cdbff5cb18a333f07af8834ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. G. Targher
3. M. Rinella
4. Gerald I. Shulman
5. R. Loomba
6. Christopher D. Byrne
7. C. Day
8. S. Friedman

In Epidemiology

1. Z. Younossi
2. G. Targher
3. M. Rinella
4. Gerald I. Shulman
5. Christopher D. Byrne
6. A. Sanyal
7. K. Cusi
8. R. Loomba

In Hepatology

1. Z. Younossi
2. M. Rinella
3. S. Friedman
4. Gerald I. Shulman
5. G. Targher
6. R. Loomba
7. E. Brunt
8. K. Cusi

Citations in the corpus

• Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, background): “[ 42] None the less these findings highlight the significant burden of MASLD in Asia.”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “The long term outcomes of patients with NAFLD and NASH have been reported in several studies.(31,38-45) Their detailed discussion is beyond the scope of this guideline, but their findings can be summarized as follows; (a) patients with NAFLD have increased overall mortality compared to matched contr”
• Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. (2014, background): “secondary to other forms of chronic liver disease, such as HBV or HCV.(8-17) For example, Ascha et al.”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “The fibrosis stage is important for monitoring the clinical risk of progression to cirrhosis and long-term liver-related outcomes and mortality.((6)) Most liver-related outcomes occur once cirrhosis has developed, with the exception of hepatocellular carcinoma (HCC) that can occur even in the absenc”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Long-term follow-up studies have shown that NASH increases overall mortality by 35–85% compared to the age and sex-matched general population [51,70,71].”
• The interaction of hepatic lipid and glucose metabolism in liver diseases. (2012, background): “Several studies could recently dissect the effects of individual confounders of the metabolic syndrome and clearly demonstrate a significant risk for NAFLD patients to develop HCC [120].”